Clinical Trial Update: Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating mavoglurant (AFQ056) for reducing chorea in Huntington's disease was terminated. The update notes the study's status but does not pro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• Mavoglurant (mavoglurant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Huntington's Disease, Chorea | Phase 2 | Status: TERMINATED